Sanofi to acquire Vigil Neuroscience in $470 million deal
Published by Global Banking & Finance Review®
Posted on May 22, 2025
1 min readLast updated: January 23, 2026
Published by Global Banking & Finance Review®
Posted on May 22, 2025
1 min readLast updated: January 23, 2026
Sanofi is set to acquire Vigil Neuroscience for $470 million, enhancing its biotech portfolio. The deal values Vigil at $8 per share.
(Reuters) -Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million.
(Reporting by Bipasha Dey in Bengaluru; Editing by Mohammed Safi Shamsi)
Sanofi will acquire Vigil Neuroscience for $8 per share in cash.
The acquisition is valued at approximately $470 million.
The news was reported by Bipasha Dey in Bengaluru.
Explore more articles in the Finance category




